AF is the most common arrhythmia in the elderly, and it is an independent risk factor for stroke [2]. Also, the prevalence of frailty increases steadily with age, from approximately 4% at 65-69 years of age to nearly 26% at 85 years or above [3]. It is estimated that non-valvular AF patients have a 4-times higher odds of being classified as frail than patients without non-valvular AF [4], and despite the high prevalence of AF among frail elderly patients, fewer frail AF patients receive oral coagulants compared with non-frail patients [5,6]. Even so, very few real-world studies have examined the comparative efficacy and safety outcomes between non-vitamin K antagonist oral coagulants (DOACs) and warfarin in the frail elderly non-valvular AF population [7,8].
Prof. Gregory Lip (University of Birmingham, United Kingdom) presented the results of a retrospective, observational study of frail non-valvular AF patients who initiated apixaban, dabigatran, rivaroxaban, or warfarin using Medicare data and 3 US commercial claims databases. Frailty was defined using the algorithm defined by Segal et al. The results showed that among non-valvular AF patients aged ≥65 years (n=258,989), 38% met frailty criteria. They identified 98,375 frail patients with non-valvular AF, including 18.8% on apixaban, 6.4% on dabigatran, 26.1% on rivaroxaban, and 48.7% warfarin patients. The mean frailty indicator score was 0.4. Before propensity score matching (PSM), >90% of patients had CHA2DS2-VASc scores ≥4, and >80% had HAS-BLED scores ≥3. After PSM, 17,750 apixaban-warfarin, 6,204 dabigatran-warfarin, and 24,388 rivaroxaban-warfarin PSM pairs were included in the analysis. The mean follow-up time was 7-8 months. After PSM, all baseline characteristics were balanced between the matched cohorts. Approximately 50.5% of apixaban, 38.6% of dabigatran, and 52.3% of rivaroxaban (10 or 15 mg) patients were on a lower dose (2.5 mg, 75 mg, and 10 or 15 mg, respectively).
Compared with warfarin, all DOACs were associated with a lower risk of stroke/SE. Apixaban and rivaroxaban patients had a lower risk of ischaemic stroke compared with warfarin patients. Apixaban and dabigatran use were associated with a lower risk of haemorrhagic stroke vs warfarin use, and apixaban was associated with a lower risk of major bleeding compared with warfarin. Dabigatran was associated with a similar risk and rivaroxaban was associated with a higher risk of major bleeding compared with warfarin. Gastrointestinal bleeding was the most prevalent type of major bleeding with apixaban being associated with a lower risk and dabigatran and rivaroxaban associated with a higher risk vs warfarin. All DOACs were associated with a lower intracerebral haemorrhage risk vs warfarin.
- Lip GYH, et al. J Am Coll Cardiol. 2019;73(9):432. DOI: 10.1016/S0735-1097(19)31040-X.
- Fumagalli S, et al. Aging Clin Exp Res. 2010;22(2):129-133.
- Song X, et al. J Am Geriatr Soc. 2010;58(4):681-7.
- Polidori A, et al. Arch Gerontol Geriatr. 2013;57(3):325-7.
- Oqab Z, et al. J Atr Fibrillation. 2018;10(6):1870.
- Induruwa I, et al. Geriatr Gerontol Int. 2017;17(11):2178-2183.
- Martinez BK, et al. J Am Heart Assoc. 2018;7(8):e008643.
- Ozaki M, et al. J Am Coll Cardiol. 2018;71(11):A286.
Posted on
Previous Article
« Similar rates of stroke/SE associated with DOAC vs warfarin use in obese non-valvular AF patients: Results from an observational registry Next Article
Similar MACE rates but higher all-cause mortality in PAD patients with diabetes »
« Similar rates of stroke/SE associated with DOAC vs warfarin use in obese non-valvular AF patients: Results from an observational registry Next Article
Similar MACE rates but higher all-cause mortality in PAD patients with diabetes »
Table of Contents: ACC 2019
Featured articles
Acute and Stable Ischaemic Heart Disease
Arrhythmias and Clinical Electrophysiology
Substantial impact of temporary interruptions of warfarin versus DOAC
Smartwatch can detect atrial fibrillation with high degree of accuracy
Congenital Heart Disease
Heart Failure and Cardiomyopathies
Frequent use of beta-blocker after HFpEF hospitalisations in elderly patients without compelling indications
High 5-year survival rates for older HF patients without initial severe comorbidity
Pulmonary Arterial Hypertension and Venous Thromboembolism
Interventional Cardiology
Vascular Medicine
Lower rates stroke/SE with DOACs in frail non-valvular AF patients
Similar rates of stroke/SE associated with DOAC vs warfarin use in obese non-valvular AF patients: Results from an observational registry
Convincing evidence of the role of icosapent in reducing subsequent CV events
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy